@article{JTD7944,
author = {Shuang-Jiang Li and Jian Huang and Xu-Dong Zhou and Wen-Biao Zhang and Yu-Tian Lai and Guo-Wei Che},
title = {Clinicopathological and prognostic significance of Oct-4 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis},
journal = {Journal of Thoracic Disease},
volume = {8},
number = {7},
year = {2016},
keywords = {},
abstract = {Background: Octamer-binding transcription factor 4 (Oct-4) has been identified to participate in the tumorigenicity and malignancy of non-small cell lung cancer (NSCLC). However, its definite prognostic roles in NSCLC still remain a debate. Therefore, we conducted this meta-analysis to evaluate the prognostic value of Oct-4 expression in NSCLC and its relationship to some major clinicopathological characteristics.
Methods: A comprehensive literature retrieval was performed in PubMed, EMBASE and the Web of Science to identify the full-text articles that met our eligibility criteria. Odds ratio (OR) with 95% confidence interval (CI) severed as the summarized statistics for clinicopathological assessments, and hazard ratio (HR) with 95% CI served as the summarized statistics for prognostic assessments. Q-test and I2-statistic were used to evaluate the level of heterogeneity. Potential publication bias was detected by both Begg’s test and Egger’s test.
Results: There were 16 retried articles with 1,363 NSCLC cases included into this meta-analysis. Oct-4 expression was found to be significantly associated with the unfavorable outcomes for differentiation degree (OR: 3.065; 95% CI: 1.568–5.957; P=0.001), TNM stage (OR: 3.695; 95% CI: 2.252–6.063; P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/7944}
}